Hepatitis B

Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-99.Texto completo  Resumen

European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-98.Texto completo  Resumen

Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-99.Texto completo  Resumen

1. Mohanty SR, Kupfer SS, Khiani V. Treatment of chronic hepatitis B. Nat Clin Pract Gastroenterol Hepatol. 2006 Aug;3(8):446-58. Resumen

2. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-99.Texto completo  Resumen

3. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology. 2002 May;35(5):1274-6.Texto completo  Resumen

4. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut. 2005 Jul;54(7):1009-13.Texto completo  Resumen

5. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005 Jan 8-14;365(9454):123-9. Resumen

6. Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol. 2000 Dec;33(6):998-1002. Resumen

7. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005 Jun 30;352(26):2682-95. Resumen

8. Liu Z, Zhang Y, Xu M, et al. Distribution of hepatitis B virus genotypes and subgenotypes: a meta-analysis. Medicine (Baltimore). 2021 Dec 17;100(50):e27941.Texto completo  Resumen

9. World Health Organization. Hepatitis B: fact sheet. Jul 2023 [internet publication].Texto completo

10. Alberts CJ, Clifford GM, Georges D, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol. 2022 Aug;7(8):724-35.Texto completo  Resumen

11. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol. 2003;39 Suppl 1:S64-9. Resumen

12. Trickey A, Bivegete S, Duffell E, et al. Estimating hepatitis B virus prevalence among key population groups for European Union and European Economic Area countries and the United Kingdom: a modelling study. BMC Infect Dis. 2023 Jul 10;23(1):457.Texto completo  Resumen

13. Centers for Disease Control and Prevention. Viral hepatitis surveillance - United States: hepatitis B surveillance 2021. Aug 2023 [internet publication].Texto completo

14. Wong RJ, Brosgart CL, Welch S, et al. An updated assessment of chronic hepatitis B prevalence among foreign-born persons living in the United States. Hepatology. 2021 Aug;74(2):607-26.Texto completo  Resumen

15. UK Health Security Agency. Hepatitis B (in England). Feb 2023​ [internet publication].Texto completo

16. GBD 2019 Europe Hepatitis B & C Collaborators. Hepatitis B and C in Europe: an update from the global burden of disease study 2019. Lancet Public Health. 2023 Sep;8(9):e701-16.Texto completo  Resumen

17. Khetsuriani N, Lesi O, Desai S, et al. Progress toward the elimination of mother-to-child transmission of hepatitis B virus - worldwide, 2016-2021. MMWR Morb Mortal Wkly Rep. 2022 Jul 29;71(30):958-63.Texto completo  Resumen

18. Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):466-76. Resumen

19. ​UK Health Security Agency. Mother-to-child transmission of hepatitis B eliminated in England. Feb 2023 [internet publication].Texto completo

20. Ji DZ, Pang XY, Shen DT, et al. Global prevalence of occult hepatitis B: a systematic review and meta-analysis. J Viral Hepat. 2022 May;29(5):317-29. Resumen

21. Im YR, Jagdish R, Leith D, et al. Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022 Oct;7(10):932-42.Texto completo  Resumen

22. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997 Dec 11;337(24):1733-45. Resumen

23. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med. 2004 Mar 11;350(11):1118-29. Resumen

24. Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999 Apr 30;284(5415):825-9. Resumen

25. Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996 Jan;4(1):25-36. Resumen

26. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995;13:29-60. Resumen

27. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell. 1986 Nov 7;47(3):451-60. Resumen

28. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000 Mar;64(1):51-68.Texto completo  Resumen

29. Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science. 1986 Apr 25;232(4749):477-84. Resumen

30. Newbold JE, Xin H, Tencza M, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 1995 Jun;69(6):3350-7.Texto completo  Resumen

31. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005 Mar;42(3):302-8. Resumen

32. Yuen MF, Wong DK, Sum SS, et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol. 2005 May;100(5):1099-103. Resumen

33. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006 Sep;44(3):675-84. Resumen

34. Wong DK, Yuen MF, Ngai VW, et al. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther. 2006;11(7):909-16. Resumen

35. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004 Jun;126(7):1750-8. Resumen

36. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005 Jun;128(7):1890-7. Resumen

37. Bourne EJ, Dienstag JL, Lopez VA, et al. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. J Viral Hepat. 2007 Jan;14(1):55-63. Resumen

38. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-98.Texto completo  Resumen

39. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008 Apr;23(4):512-20.Texto completo  Resumen

40. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998 Jan 30;75(3):347-54.Texto completo  Resumen

41. Jamma S, Hussain G, Lau DT. Current concepts of HBV/HCV coinfection: coexistence, but not necessarily in harmony. Curr Hepat Rep. 2010;9(4):260-9.Texto completo  Resumen

42. Bellecave P, Gouttenoire J, Gajer M, et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology. 2009 Jul;50(1):46-55.Texto completo  Resumen

43. Ghendon Y. Perinatal transmission of hepatitis B virus in high-incidence countries. J Virol Methods. 1987 Aug;17(1-2):69-79. Resumen

44. Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis. 2002 Mar 15;185(6):713-9. Resumen

45. Rashti R, Alavian SM, Moradi Y, et al. Global prevalence of HCV and/or HBV coinfections among people who inject drugs and female sex workers who live with HIV/AIDS: a systematic review and meta-analysis. Arch Virol. 2020 Sep;165(9):1947-58.Texto completo  Resumen

46. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017 Dec;5(12):e1192-e1207.Texto completo  Resumen

47. Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis: United States, 2005. MMWR Surveill Summ. 2007 Mar 16;56(3):1-24. Resumen

48. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. March 2015 [internet publication].Texto completo

49. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis. 2003 May;23(2):125-36. Resumen

50. Strader DB. Understudied populations with hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S226-36. Resumen

51. Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology. 2017 Jul;66(1):13-26.Texto completo  Resumen

52. Mücke MM, Backus LI, Mücke VT, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):172-80. Resumen

53. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002 Aug;42(8):975-9. Resumen

54. Mahoney FJ, Stewart K, Hu H, et al. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch Intern Med. 1997 Dec 8-22;157(22):2601-5. Resumen

55. Harpaz R, Von Seidlein L, Averhoff FM, et al. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med. 1996 Feb 29;334(9):549-54. Resumen

56. Lettau LA, Smith JD, Williams D, et al. Transmission of hepatitis B with resultant restriction of surgical practice. JAMA. 1986 Feb 21;255(7):934-7. Resumen

57. Singh J, Stoitsova S, Zakrzewska K, et al. Healthcare-associated hepatitis B and C transmission to patients in the EU/EEA and UK: a systematic review of reported outbreaks between 2006 and 2021. BMC Public Health. 2022 Dec 3;22(1):2260.Texto completo  Resumen

58. Bond WW, Favero MS, Petersen NJ, et al. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981 Mar 7;1(8219):550-1. Resumen

59. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet. 1989 Apr 22;1(8643):889-93. Resumen

60. Falla AM, Hofstraat SHI, Duffell E, et al. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis. 2018 Feb 12;18(1):79.Texto completo  Resumen

61. Cendoroglo Neto M, Draibe SA, Silva AE, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among hemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant. 1995;10(2):240-6. Resumen

62. Khalesi Z, Razizadeh MH, Javadi M, et al. Global epidemiology of HBV infection among hemodialysis patients: A systematic review and meta-analysis. Microb Pathog. 2023 Jun;179:106080. Resumen

63. Malinis M, Boucher HW, AST Infectious Diseases Community of Practice. Screening of donor and candidate prior to solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13548.Texto completo  Resumen

64. Bixler D, Annambhotla P, Montgomery MP, et al. Unexpected hepatitis B virus infection after liver transplantation - United States, 2014-2019. MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):961-6.Texto completo  Resumen

65. Centers for Disease Control and Prevention. Immunization schedules: recommended child and adolescent immunization schedule for ages 18 years or younger - United States, 2023. Feb 2023 [internet publication].Texto completo

66. American College of Obstetricians and Gynecologists. Clinical practice guideline no. 6: viral hepatitis in pregnancy. Sep 2023 [internet publication].Texto completo

67. Public Health England. Hepatitis B: the green book, chapter 18. Feb 2022 [internet publication].Texto completo

68. Centers for Disease Control and Prevention. Immunization schedules: recommended adult immunization schedule for ages 19 years or older - United States, 2023. Feb 2023 [internet publication].Texto completo

69. Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009 May;49(5 suppl):S13-21.Texto completo  Resumen

70. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985 Apr;151(4):599-603. Resumen

71. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991 Jan;100(1):182-8.Texto completo  Resumen

72. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003 Jul;62(7):686-7.Texto completo  Resumen

73. Amini A, Varsaneux O, Kelly H, et al. Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis. BMC Infect Dis. 2017 Nov 1;17(suppl 1):698.Texto completo  Resumen

74. Chou C, Veracruz N, Chitnis AS, et al. Risk of drug-induced liver injury in chronic hepatitis B and tuberculosis co-infection: a systematic review and meta-analysis. J Viral Hepat. 2022 Dec;29(12):1107-14. Resumen

75. Wong RJ, Hubbard A, Bagley L, et al. Estimating prevalence of hepatitis B virus coinfection among adults with tuberculosis: a systematic review with meta-analysis. J Clin Gastroenterol. 2022 Aug 1;56(7):601-17. Resumen

76. West J, Card TR. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology. 2010 Oct;139(4):1230-7.Texto completo  Resumen

77. Cardoso AC, Carvalho-Filho RJ, Marcellin P. Transient elastography in chronic viral hepatitis: a critical appraisal. Gut. 2011 Jun;60(6):759-64. Resumen

78. Cardoso AC, Carvalho-Filho RJ, Stern C, et al. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int. 2012 Apr;32(4):612-21. Resumen

79. Castéra L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepatol. 2009 May;16(5):300-14. Resumen

80. Castéra L, Bernard PH, Le Bail P, et al. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. Aliment Pharmacol Ther. 2011 Feb;33(4):455-65.Texto completo  Resumen

81. Fraquelli M, Branchi F. The role of transient elastography in patients with hepatitis B viral disease. Dig Liver Dis. 2011 Jan;43 Suppl 1:S25-31. Resumen

82. Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009 Feb;29(2):242-7. Resumen

83. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol. 2007;7:40.Texto completo  Resumen

84. Yin Z, Zou J, Li Q, et al. Diagnostic value of FIB-4 for liver fibrosis in patients with hepatitis B: a meta-analysis of diagnostic test. Oncotarget. 2017 Apr 4;8(14):22944-53.Texto completo  Resumen

85. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008 Feb;47(2):380-4.Texto completo  Resumen

86. Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011 Apr;54(4):650-9. Resumen

87. Xiao H, Shi M, Xie Y, et al. Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis. PLoS One. 2017 Nov 6;12(11):e0186660.Texto completo  Resumen

88. Centers for Disease Control and Prevention. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR Recomm Rep. 1991 Apr 19;40(RR-4):1-17. Resumen

89. Saldanha J, Gerlich W, Lelie N, et al; WHO Collaborative Study Group. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang. 2001 Jan;80(1):63-71. Resumen

90. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006 Mar;101(3):513-23. Resumen

91. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003 Jul 1;139(1):46-50. Resumen

92. Soresi M, Magliarisi C, Campagna P, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003 Mar-Apr;23(2C):1747-53. Resumen

93. Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and testing for hepatitis B virus infection: CDC recommendations - United States, 2023. MMWR Recomm Rep. 2023 Mar 10;72(1):1-25.Texto completo  Resumen

94. US Preventive Services Task Force. Final recommendation statement. Hepatitis B virus infection in adolescents and adults: screening. Dec 2020 [internet publication].Texto completo

95. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020 Nov 1;38(31):3698-715.Texto completo  Resumen

96. Mantzoukis K, Rodríguez-Perálvarez M, Buzzetti E, et al. Pharmacological interventions for acute hepatitis B infection. Cochrane Database Syst Rev. 2017 Mar 21;(3):CD011645.Texto completo  Resumen

97. Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010 Aug;53(2):348-56. Resumen

98. Wong GL, Yiu KK, Wong VW, et al. Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2010 Nov;32(9):1059-68.Texto completo  Resumen

99. Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008 Nov 1;28(9):1067-77. Resumen

100. Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol. 2009;44(5):470-5. Resumen

101. Tang LSY, Covert E, Wilson E, et al. Chronic hepatitis B infection: a review. JAMA. 2018 May 1;319(17):1802-13. Resumen

102. Lampertico P, Buti M, Fung S, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020 May;5(5):441-53. Resumen

103. Lim YS, Seto WK, Kurosaki M, et al. Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther. 2022 Apr;55(8):921-43.Texto completo  Resumen

104. Chan HLY, Buti M, Lim YS, et al. Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety. Am J Gastroenterol. 2023 Aug 10.Texto completo  Resumen

105. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007 Nov;133(5):1437-44. Resumen

106. Yim HJ, Kim JH, Park JY, et al. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020 Oct;26(4):411-29.Texto completo  Resumen

107. Choi WM, Yip TC, Wong GL, et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. J Hepatol. 2023 Mar;78(3):534-42.Texto completo  Resumen

108. Tang K, Cheng H, Wang H, et al. Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B. Medicine (Baltimore). 2023 Feb 10;102(6):e32894.Texto completo  Resumen

109. Tseng CH, Hsu YC, Chen TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 Dec;5(12):1039-52.Texto completo  Resumen

110. Huang ZH, Lu GY, Qiu LX, et al. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis. BMC Cancer. 2022 Mar 17;22(1):287.Texto completo  Resumen

111. Tan DJH, Ng CH, Tay PWL, et al. Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis. JAMA Netw Open. 2022 Jun 1;5(6):e2219407.Texto completo  Resumen

112. Giri S, Agrawal D, Afzalpurkar S, et al. Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: a systematic review and meta-analysis. J Viral Hepat. 2023 Feb;30(2):108-15. Resumen

113. Liu H, Han CL, Tian BW, et al. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2023 Jan-Jun;17(6):623-33. Resumen

114. Carosi G, Rizzetto M, Alberti A, et al. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis. 2011 Apr;43(4):259-65. Resumen

115. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521-31.Texto completo  Resumen

116. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology. 2005 Jul;42(1):121-9.Texto completo  Resumen

117. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010 Sep;52(3):886-93.Texto completo  Resumen

118. Buster EH, Hansen BE, Buti M, et al; HBV 99-01 Study Group. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology. 2007 Aug;46(2):388-94.Texto completo  Resumen

119. Yao Y, Zhang J, Li X, et al. Systematic review: clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis. Front Public Health. 2022;10:1037527.Texto completo  Resumen

120. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995 Sep;109(3):908-16. Resumen

121. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009 Dec;50(6):2001-6.Texto completo  Resumen

122. Altfeld M, Rockstroh JK, Addo M, et al. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol. 1998 Aug;29(2):306-9. Resumen

123. National Institutes of Health, Centers for Disease Control and Prevention, and HIV Medicine Association of the Infectious Disease Society of America Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: hepatitis B virus infection. 2023 [internet publication].Texto completo

124. Jiang XW, Ye JZ, Li YT, et al. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J Gastroenterol. 2018 Jul 28;24(28):3181-91.Texto completo  Resumen

125. Yurdaydın C, Idilman R, Bozkaya H, et al. Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010 Nov;17(11):749-56. Resumen

126. World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. Jul 2020 [internet publication].Texto completo

127. Funk AL, Lu Y, Yoshida K, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2021 Jan;21(1):70-84.Texto completo  Resumen

128. Ugwu EO, Eleje GU, Ugwu AO, et al. Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus. Cochrane Database Syst Rev. 2023 Jun 12;6(6):CD013653. Resumen

129. Hyun MH, Lee YS, Kim JH, et al. Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. Aliment Pharmacol Ther. 2017 Jun;45(12):1493-505. Resumen

130. Li W, Jia L, Zhao X, et al. Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries. BMC Gastroenterol. 2018 Aug 2;18(1):121.Texto completo  Resumen

131. Tavakolpour S, Darvishi M, Mirsafaei HS, et al. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review. Infect Dis (Lond). 2017 Oct 11;50(2):95-106. Resumen

132. Zhu L, Park J, Deng Y, et al. The use of tenofovir disoproxil fumarate and tenofovir alafenamide for preventing vertical transmission of hepatitis B. J Clin Gastroenterol. 2023 Feb 1;57(2):127-38. Resumen

133. Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011 Dec;55(6):1215-21. Resumen

134. Shi Z, Yang Y, Ma L, et al. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: systematic review and meta-analysis. Obstet Gynecol. 2010 Jul;116(1):147-59. Resumen

135. Su GG, Pan KH, Zhao NF, et al. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol. 2004 Mar 15;10(6):910-2. Resumen

136. van Zonneveld M, van Nunen AB, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003 Jul;10(4):294-7. Resumen

137. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009 Feb;16(2):94-103. Resumen

138. He R, Wen P, Xiong M, et al. Cesarean section in reducing mother-to-child HBV transmission: a meta-analysis. J Matern Fetal Neonatal Med. 2022 Sep;35(18):3424-32. Resumen

139. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of liver diseases in pregnancy. J Hepatol. 2023 Sep;79(3):768-828.Texto completo  Resumen

140. Shi Z, Yang Y, Wang H, et al. Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. Arch Pediatr Adolesc Med. 2011 Sep;165(9):837-46. Resumen

141. Li M, Li Q, Qu J, et al. The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2023 Feb;17(1):52-62. Resumen

142. Lampertico P, Buti M, Fung S, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020 May;5(5):441-53. Resumen

143. Lim YS, Seto WK, Kurosaki M, et al. Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther. 2022 Apr;55(8):921-43.Texto completo  Resumen

144. Chan HLY, Buti M, Lim YS, et al. Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety. Am J Gastroenterol. 2023 Aug 10.Texto completo  Resumen

145. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-99.Texto completo  Resumen

146. Yao Y, Zhang J, Li X, et al. Systematic review: clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis. Front Public Health. 2022;10:1037527.Texto completo  Resumen

147. Hyun MH, Lee YS, Kim JH, et al. Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. Aliment Pharmacol Ther. 2017 Jun;45(12):1493-505. Resumen

148. Li W, Jia L, Zhao X, et al. Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries. BMC Gastroenterol. 2018 Aug 2;18(1):121.Texto completo  Resumen

149. Tavakolpour S, Darvishi M, Mirsafaei HS, et al. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review. Infect Dis (Lond). 2017 Oct 11;50(2):95-106. Resumen

150. Zhu L, Park J, Deng Y, et al. The use of tenofovir disoproxil fumarate and tenofovir alafenamide for preventing vertical transmission of hepatitis B. J Clin Gastroenterol. 2023 Feb 1;57(2):127-38. Resumen

151. Papatheodoridi M, Papatheodoridis GV. State-of-the-art and emerging antivirals for chronic hepatitis B infection. Expert Opin Pharmacother. 2022 Dec;23(18):1999-2012. Resumen

152. Bloom K, Maepa MB, Ely A, et al. Gene therapy for chronic HBV-can we eliminate cccDNA? Genes (Basel). 2018 Apr 12;9(4).Texto completo  Resumen

153. Soriano V, Sherman KE, Barreiro P. Hepatitis delta and HIV infection. AIDS. 2017 Apr 24;31(7):875-84. Resumen

154. Hepatitis B Foundation. Treatment options: drug watch. Dec 2023 [internet publication].Texto completo

155. Wang Y, Xiong J, Niu M, et al. Statins and the risk of cirrhosis in hepatitis B or C patients: a systematic review and dose-response meta-analysis of observational studies. Oncotarget. 2017 Jul 27;8(35):59666-76.Texto completo  Resumen

156. Simon TG, Duberg AS, Aleman S, et al. Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide Swedish population. Ann Intern Med. 2019 Sep 3;171(5):318-27.Texto completo  Resumen

157. Vahedian-Azimi A, Shojaie S, Banach M, et al. Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants. Ann Med. 2021 Dec;53(1):1227-42.Texto completo  Resumen

158. Li Z, Li Y, Li X, et al. Statins in Hepatitis B or C patients is associated with reduced hepatocellular carcinoma risk: a systematic review and meta-analysis. Turk J Gastroenterol. 2022 Feb;33(2):136-44.Texto completo  Resumen

159. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996 May 30;334(22):1422-7. Resumen

160. Gish RG, Chang TT, Lai CL, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2010 Jan;17(1):16-22. Resumen

161. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006 Feb;43(2 Suppl 1):S173-81. Resumen

162. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 May;142(6):1264-73.e1.Texto completo  Resumen

163. Chang TE, Su CW, Huang YS, et al. Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis. J Chin Med Assoc. 2022 Jan 1;85(1):30-41.Texto completo  Resumen

164. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005 May;9(2):191-211, v. Resumen

165. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002 Jul 18;347(3):168-74. Resumen

166. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006 Mar;130(3):678-86. Resumen

167. Kuang XJ, Jia RR, Huo RR, et al. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Viral Hepat. 2018 May 2;25(9):1026-37. Resumen

168. Tsuboi R, Sanada T, Takamori K, et al. Isolation and properties of extracellular proteinases from Sporothrix schenckii. J Bacteriol. 1987 Sep;169(9):4104-9.Texto completo  Resumen

169. Kamal H, Fornes R, Simin J, et al. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: a systematic review and meta-analysis of longitudinal studies. J Viral Hepat. 2021 Oct;28(10):1431-42.Texto completo  Resumen

170. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017 May;152(6):1297-309.Texto completo  Resumen

171. Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020 Sep 1;370:m2200.Texto completo  Resumen

172. Papatheodoridi M, Tampaki M, Lok AS, et al. Risk of HBV reactivation during therapies for HCC: a systematic review. Hepatology. 2022 May;75(5):1257-74.Texto completo  Resumen

173. Smedile A, Farci P, Verme G, et al. Influence of delta infection on severity of hepatitis B. Lancet. 1982 Oct 30;2(8305):945-7. Resumen

174. Feray C, Gigou M, Samuel D, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology. 1993 Feb;104(2):549-55. Resumen

175. Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther. 2006 Sep 1;24(5):781-8. Resumen

176. Kamiza AB, Fatumo S, Singini MG, et al Hepatitis B infection is causally associated with extrahepatic cancers: a Mendelian randomization study. EBioMedicine. 2022 May;79:104003.Texto completo  Resumen

177. Lee DH, Chung SW, Lee JH, et al. Association of chronic hepatitis B infection and antiviral treatment with the development of the extrahepatic malignancies: a nationwide cohort study. J Clin Oncol. 2022 Oct 10;40(29):3394-405. Resumen

178. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007 Feb;45(2):507-39.Texto completo  Resumen

179. Buti M, Wong DK, Gane E, et al. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. Lancet Gastroenterol Hepatol. 2019 Apr;4(4):296-304. Resumen

180. World Health Organization. New good practice statement on counselling behavioural interventions for key populations to prevent HIV, viral hepatitis and STIs​. Jun 2023 [internet publication].Texto completo